Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy

Bibliography

• Chobanian AV, Bakris GL, Black HR, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Ritchie LD, Campbell NC, Murchie P. New NICE guidelines for hypertension. BMJ 2011;343:d5644
   Google Scholar
• Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 2004;5:155-60
   PubMed Web of Science ®Google Scholar
• Al Badarin FJ, Abuannadi MA, Lavie CJ, Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. Am J Cardiol 2011;107:1178-84
   PubMed Web of Science ®Google Scholar
• NICE. Hypertension Clinical Management of Primary Hypertension in Adults. National Institute for Health and Clinical Excellence 2011;Clinical guideline 127
   Google Scholar
• Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Rationale for use in hypertension. Clin Pharmacokinet 1999;37(Suppl 1):7-12
   PubMedGoogle Scholar
• Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs 2006;66:257-71
   PubMed Web of Science ®Google Scholar
• Matheson AJ, Cheer SM, Goa KL. Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs 2001;61:1211-29
   PubMed Web of Science ®Google Scholar
• Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 1983;106:237-44
   PubMed Web of Science ®Google Scholar
• Onesti G, Pitone JM, Lowenthal DL, Studies on the natriuretic effect and site of action of indapamide. Curr Med Res Opin 1977;5:1-83
   Web of Science ®Google Scholar
• Isaac R, Witchitz S, Kamoun A, A long-term study of the influence of indapamide on the exchangeable potassium and sodium pools in hypertensive patients. Curr Med Res Opin 1977;5:64-70
   PubMed Web of Science ®Google Scholar
• LeBel M, Grose JH, Belleau LJ, Antihypertensive effect of indapamide with special emphasis on renal prostaglandin production. Curr Med Res Opin 1983;8(Suppl 3):81-6
   PubMed Web of Science ®Google Scholar
• Campbell DB. The possible mode of action of indapamide: a review. Curr Med Res Opin 1983;8(Suppl 3):9-24
   PubMedGoogle Scholar
• Grimm M, Weidmann P, Meier A, Correction of altered noradrenaline reactivity in essential hypertension by indapamide. Br Heart J 1981;46:404-9
   PubMedGoogle Scholar
• Velasco M, Urbina-Quintana A, Hernandez-Pieretti O. Cardiovascular hemodynamic effects of indapamide and atenolol in hypertensive patients. Curr Ther Res 1982;31:1007-17
   Web of Science ®Google Scholar
• Mironneau J, Savineau JP, Mironneau C. Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. Eur J Pharmacol 1981;75:109-13
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Safar M, Degaute JP, Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens 1998;16:1677-84
   PubMed Web of Science ®Google Scholar
• Mallion JM, Asmar R, Boutelant S, Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998;32:673-8
   PubMed Web of Science ®Google Scholar
• Baguet JP, Robitail S, Boyer L, A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005;5:131-40
   PubMedGoogle Scholar
• London G, Schmieder R, Calvo C, Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens 2006;19:113-21
   PubMed Web of Science ®Google Scholar
• Mallion JM, Asmar R, Ambrosioni E, Evaluation of trough/peak ratio of indapamide 1.5 mg sustained-release form assessed by ambulatory blood pressure monitoring. Arch Mal Coeur Vaiss 1996;89(4):27-38
   PubMedGoogle Scholar
• Zhang Y, Agnoletti D, Safar ME, Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011;58:155-60
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G, Hennig M, Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001;19:1981-9
   PubMed Web of Science ®Google Scholar
• Sega R, Corrao G, Bombelli M, Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002;39:710-14
   PubMed Web of Science ®Google Scholar
• Akram J, Sheikh UE, Mahmood M, Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. Curr Med Res Opin 2007;23:2929-36
   PubMed Web of Science ®Google Scholar
• Laurent S. Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. J Hypertens Suppl 2001;19:S9-14
   PubMedGoogle Scholar
• Chalmers J, Castaigne A, Morgan T, Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327-37
   PubMed Web of Science ®Google Scholar
• Kang S, Wu YF, An N, A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther 2004;26:257-70
   PubMed Web of Science ®Google Scholar
• Mourad JJ, Nguyen V, Lopez-Sublet M, Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial. Vasc Health Risk Manag 2007;3:173-80
   PubMedGoogle Scholar
• Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev 2011;18:107-13
   PubMedGoogle Scholar
• Brunner H, Cockcroft JR, Deanfield J, Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-46
   PubMed Web of Science ®Google Scholar
• Modena MG, Bonetti L, Coppi F, Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002;40:505-10
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Magagna A, Kardasz I, Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hypertens 2009;22:506-12
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockcroft J, Van Bortel L, Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605
   PubMed Web of Science ®Google Scholar
• Asmar RG, London GM, O'Rourke ME, Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922-6
   PubMed Web of Science ®Google Scholar
• Puig JG, Marre M, Kokot F, Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens 2007;20:90-7
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Schlaich MP, Klingbeil AU, Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-9
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54
   PubMed Web of Science ®Google Scholar
• Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110
   PubMed Web of Science ®Google Scholar
• Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. J Hypertens Suppl 1998;16:29-34
   Google Scholar
• Gosse P, Sheridan DJ, Zannad F, Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18:1465-75
   PubMed Web of Science ®Google Scholar
• Dahlof B, Gosse P, Gueret P, Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063-70
   PubMed Web of Science ®Google Scholar
• de Luca N, Mallion JM, O'Rourke MF, Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660-7
   PubMed Web of Science ®Google Scholar
• Treasure CB, Klein JL, Vita JA, Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993;87:86-93
   PubMed Web of Science ®Google Scholar
• Gimelli A, Schneider-Eicke J, Neglia D, Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with degree of hypertrophy. J Am Coll Cardiol 1998;31:366-73
   PubMed Web of Science ®Google Scholar
• Schwartzkopff B, Motz W, Frenzel H, Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993;88:993-1003
   PubMed Web of Science ®Google Scholar
• Cecchi F, Olivotto I, Gistri R, Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35
   PubMed Web of Science ®Google Scholar
• Mourad JJ, Hanon O, Deverre JR, Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 2003;4:94-5
   PubMed Web of Science ®Google Scholar
• Neglia D, Fommei E, Varela-Carver A, Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens 2011;29:364-72
   PubMed Web of Science ®Google Scholar
• Bigazzi R, Bianchi S, Baldari D, Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325-33
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-89
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Henry RM, Dekker JM, Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction–the Hoorn Study. Kidney Int Suppl 2004;66(suppl 92):S42-4
   Google Scholar
• Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010;28:2357-69
   PubMed Web of Science ®Google Scholar
• Marre M, Puig JG, Kokot F, Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004;22:1613-22
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Viberti G, Halimi S, Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063-71
   PubMed Web of Science ®Google Scholar
• Madkour H, Gadallah M, Riveline B, Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Am J Cardiol 1996;77:23B-5B
   PubMed Web of Science ®Google Scholar
• Brennan L, Wu MJ, Laquer UJ. A multicenter study of indapamide in hypertensive patients with impaired renal function. Clin Ther 1982;5:121-8
   PubMed Web of Science ®Google Scholar
• Group PC. Randomised trial of a peridopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial) : a randomised controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ, Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227-76
   PubMed Web of Science ®Google Scholar
• de Galan BE, Perkovic V, Ninomiya T, Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92
   PubMed Web of Science ®Google Scholar
• Garc ADJA, Segura J, Cerezo C, A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Press 2011;20:322-34
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3
   PubMed Web of Science ®Google Scholar
• Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005;229-230:151-5
   PubMed Web of Science ®Google Scholar
• Beckett N, Peters R, Tuomilehto J, Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the very elderly randomised controlled trial. BMJ 2012;344:344
   Google Scholar
• Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) 2004;6:532-40
   PubMedGoogle Scholar
• Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001;24:443-56
   PubMed Web of Science ®Google Scholar
• Lakshman MR, Reda DJ, Materson BJ, Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999;159:551-8
   PubMed Web of Science ®Google Scholar
• Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf 2001;24:1155-65
   PubMed Web of Science ®Google Scholar
• Myers MG, Asmar R, Leenen FH, Fixed low-dose combination therapy in hypertension–a dose response study of perindopril and indapamide. J Hypertens 2000;18:317-25
   PubMed Web of Science ®Google Scholar